QIAGEN launches FFPE and Liquid Biopsy PIK3CA diagnostics in Europe to enhance precision medicine in advanced breast cancer
Germantown, Maryland, and Hilden, Germany, February 3, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen® PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation. Last year the therascreen PIK3CA test was approved by the FDA... Read more